Clinical Trial

A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 21, 2025 (before its estimated March 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn about the safety profile of niraparib in adult female participants for the treatment of advanced or relapsed epithelial ovarian cancer.
Trial Details
NCT Number NCT06887933
Lead Sponsor GlaxoSmithKline
Conditions Ovarian Neoplasms
Enrollment 67 participants
Start Date 2025-04-22
Primary Completion 2026-03-20 (estimated)
Study Completion 2026-07-08 (estimated)
Updated on ClinicalTrials.gov 2025-03-21